Search results for "Transaminase"

showing 10 items of 145 documents

Guinea pig transglutaminase immunolinked assay does not predict coeliac disease in patients with chronic liver disease

2001

BACKGROUND—It has been suggested that serological screening for coeliac disease (CD) should be performed in patients with chronic unexplained hypertransaminasaemia.
AIMS—To evaluate the specificity for CD diagnosis of serum IgA antitissue transglutaminase (tTG) determination in consecutive patients with chronic hypertransaminasaemia using the most widely utilised ELISA based on tTG from guinea pig as the antigen.
PATIENTS AND METHODS—We studied 98 patients with chronic hypertransaminasaemia, evaluated for the first time in a hepatology clinic. Serum anti-tTG and antiendomysial (EmA) assays were performed. Patients positive for EmA and/or anti-tTG were proposed for intestinal biopsy. Finally…

AdultLiver CirrhosisMalemedicine.medical_specialtySettore MED/09 - Medicina InternaCirrhosisAdolescentHepatitis Viral HumanTissue transglutaminaseGuinea PigsAutoimmunityEnzyme-Linked Immunosorbent AssayChronic liver diseaseSensitivity and SpecificityCoeliac diseaseArticleStatistics NonparametricAntiendomysial antibodieIntestinal histologySerologyLiver diseaseIntestinal mucosaPredictive Value of TestsInternal medicinemedicineAnimalsHumansFalse Positive ReactionsTransaminasesAutoantibodiesTransglutaminasesCoeliac diseasebiologybusiness.industryAntitissue transglutaminase antibodieGastroenterologyHepatologyMiddle Agedmedicine.diseaseImmunoglobulin ACeliac DiseaseImmunologyChronic Diseasebiology.proteinLinear ModelsFemalebusinessLiver disease
researchProduct

The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage

2016

The patatin-like phosholipase domain-containing 3 (PNPLA3) rs738409 polymorphism (I148M) is a major determinant of hepatic fat and predisposes to the full spectrum of liver damage in nonalcoholic fatty liver disease (NAFLD). The aim of this study was to evaluate whether additional PNPLA3 coding variants contribute to NAFLD susceptibility, first in individuals with contrasting phenotypes (with early-onset NAFLD vs. very low aminotransferases) and then in a large validation cohort. Rare PNPLA3 variants were not detected by sequencing coding regions and intron-exon boundaries either in 142 patients with early-onset NAFLD nor in 100 healthy individuals with alanine aminotransferase22/20 IU/mL. …

AdultMale0301 basic medicinemedicine.medical_specialtyAdolescentPolymorphism Single Nucleotide03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseLipid dropletInternal medicineNonalcoholic fatty liver diseasemedicineHumansGenetic Predisposition to DiseaseAlleleChildGeneticsHepatologybiologyMembrane ProteinsAlanine TransaminaseLipaseMiddle AgedHepatologyLipid Metabolismmedicine.diseasedigestive system diseases030104 developmental biologyEndocrinologyHaplotypesLiverAlanine transaminasePatatin-like phospholipaseadolescent; adult; alanine transaminase; case-control studies; child; female; genetic predisposition to disease; haplotypes; humans; lipase; lipid metabolism; liver; male; membrane proteins; middle aged; non-alcoholic fatty liver disease; polymorphism; single nucleotide; hepatologyCase-Control Studiesbiology.proteinFemale030211 gastroenterology & hepatologySteatosisSteatohepatitis
researchProduct

The WHO guidelines for chronic hepatitis B fail to detect half of the patients in need of treatment in Ethiopia

2019

Background & Aims In 2015, the World Health Organization (WHO) issued guidelines for the management of chronic hepatitis B (CHB) in low- and middle-income countries, but little is known about the applicability of the WHO treatment criteria in sub-Saharan Africa. The aim of this study was to evaluate the diagnostic performance of the WHO guidelines in a large CHB cohort in Ethiopia. Methods Treatment-naive adults who attended a public CHB clinic in Addis Ababa were included in this analysis. All patients underwent a standardized evaluation at recruitment, including blood tests and transient elastography (Fibroscan®). A Fibroscan result >7.9 kPa was used to define significant fibrosis and >9.…

AdultMale0301 basic medicinemedicine.medical_specialtyCirrhosisWorld Health Organization03 medical and health sciencesHepatitis B Chronic0302 clinical medicineChronic hepatitisInternal medicinemedicineHumansHepatologybusiness.industryGold standardAntiviral therapyAlanine Transaminasemedicine.disease030104 developmental biologyWho guidelinesPractice Guidelines as TopicCohortElasticity Imaging TechniquesFemale030211 gastroenterology & hepatologyEthiopiabusinessTransient elastographyViral hepatitisJournal of Hepatology
researchProduct

Circulating E-selectin levels in chronic hepatitis C patients with normal or elevated transaminase before and after alpha-interferon treatment

2001

E-selectin, an adhesion molecule of the selectin family, is involved in leukocyte adhesion to the endothelium and in the cellular immunological reactions. Expression of this molecule, in fact, is physiologically absent, but it becomes evident on sinusoidal lining cells during inflammatory liver disease. The aim of this study was to evaluate the behavior of E-selectin in chronic hepatitis C (CH-C) patients with persistently normal transaminase in comparison to patients with CH-C and elevated transaminase, and its changes during alpha-interferon therapy. Immunohistochemical localization of E-selectin was also performed on liver tissue specimens of both groups. Fifty-eight subjects were divide…

AdultMaleAdhesion moleculeChronic liver diseaseE-selectinImmunologyAlanine TransaminaseHepatitis C ChronicMiddle AgedImmunohistochemistryRecombinant ProteinsTreatmentLiverInterferon Type IHumansα-interferonImmunology and AllergyFemaleAspartate Aminotransferases
researchProduct

Problems in the management of chronic hepatitis B with interferon: experience in a randomized, multicentre study.

1990

In a multicentre trial, 82 patients known to be hepatitis B e antigen and hepatitis B virus DNA positive for at least 1 year, with elevated serum alanine aminotransferase levels and chronic liver lesions on biopsy, were randomized to receive either recombinant interferon alfa-2a at a dose of 4.5 million units thrice weekly for 4 months or no treatment. At the end of therapy, viral DNA clearance and aminotransferase normalization were significantly (p less than 0.05) more frequent in treated patients than in controls. After 16 months' follow up, the difference was still significant for hepatitis B e antigen clearance and transaminase normalization. Hepatitis B virus DNA reactivation was obse…

AdultMaleAlpha interferonInterferon alpha-2medicine.disease_causeTransaminaseLiver diseaseInterferonBiopsymedicineHumanschronic hepatitis BHepatitis B e AntigensHepatitis B virustherapyHepatitis B Surface AntigensHepatologybiologymedicine.diagnostic_testbusiness.industryInterferon-alphaAlanine TransaminaseinterferonHepatitis Bmedicine.diseaseHepatitis BRecombinant ProteinsAlanine transaminaseLiverImmunologyChronic Diseasebiology.proteinFemalechronic hepatitis B; therapy; interferonbusinessBiomarkersmedicine.drugFollow-Up StudiesJournal of hepatology
researchProduct

Screening for Autoantibodies to Tissue Transglutaminase Reveals a Low Prevalence of Celiac Disease in Blood Donors with Cryptogenic Hypertransaminase…

2001

Patients with chronic cryptogenic hypertransaminasemia are at high risk of developing celiac disease (CD). In fact, among the various serological disorders, CD patients at onset frequently present hypertransaminasemia. In this study, we evaluated usefulness and reliability of the new test for antitissue transglutaminase (tTG) in screening for CD as well as in estimating the prevalence of CD in a population of blood donors presenting unexplained hypertransaminasemia at donation. Controls were 180 consecutive healthy donors without hypertransaminasemia and 20 CD patients with known antiendomysial antibody (EmA) positivity. Out of 22,204 blood donors over a period of 2 years, we found 258 subj…

AdultMaleBlood donormedicine.medical_specialtyTissue transglutaminasePopulationE2F6 Transcription FactorBlood DonorsEnzyme-Linked Immunosorbent AssaySensitivity and SpecificityGastroenterologyCoeliac diseaseSerologyIntestinal mucosaInternal medicineImmunopathologyBiopsyPrevalencemedicineHumansCeliac diseaseIntestinal MucosaFluorescent Antibody Technique IndirecteducationTransaminasesAutoantibodieseducation.field_of_studyTransglutaminasesbiologymedicine.diagnostic_testbusiness.industryGastroenterologyAutoantibodyReproducibility of ResultsMiddle Agedmedicine.diseaseTransglutaminaseRepressor ProteinsImmunologybiology.proteinFemalebusinessTranscription FactorsDigestion
researchProduct

Are hepatitis G virus and TT virus involved in cryptogenic chronic liver disease?

2002

Abstract Background . Hepatitis G virus can cause chronic infection in man but the role of this agent in chronic liver disease is poorly understood. Little is known about the relation of another newly discovered agent, the TT virus, with chronic liver disease. Aim . To investigate the rate of infection with hepatitis G virus and TT virus in patients with cryptogenic chronic liver disease. Patients . A total of 23 subjects with chronically raised alanine transaminase and a liver biopsy in whom all known causes of liver disease had been excluded, and 4D subjects with hepatitis C virus-related chronic liver disease. Methods . Evaluation of anti-hepatitis G virus by enzyme immunoassay. Hepatiti…

AdultMaleCirrhosisHepatitis Viral HumanvirusesHepatitis C virusGB virus Cmedicine.disease_causeChronic liver diseaseLiver diseasemedicineHumansHepatitis ChronicTorque teno virusHepatitis B virusHepatitisHepatologymedicine.diagnostic_testReverse Transcriptase Polymerase Chain Reactionbusiness.industryGastroenterologyAlanine TransaminaseHepatitis CFlaviviridae InfectionsMiddle Agedmedicine.diseaseVirologyDNA Virus InfectionsLiverLiver biopsyFemalebusinessDigestive and Liver Disease
researchProduct

Endemic hepatitis C virus infection in a Sicilian town: Further evidence for iatrogenic transmission

2002

The prevalence of and risk factors for HCV and HBV infections in the general population and the predictive value of ALT screening in identifying anti-HCV positive subjects have been evaluated in a small Sicilian town. A random 1:4 sampling from the census of the general population was performed. Anti-HCV, HCV-RNA, HCV genotype, HBsAg, and anti-HBc were tested. The linkage between HCV infection and potential risk factors was evaluated by multiple logistic regression analysis. Among 721 subjects studied, 75 (10.4%) were anti-HCV positive. The HCV infection rate increased from 0.4% in subjects 10-29 years of age to 34% in those > 60 years of age. Among the 75 anti-HCV positive subjects, 66.7% …

AdultMaleEndemic DiseasesAdolescentEpidemiologyIatrogenic DiseasePredictive Value of TestEndemic DiseaseHepacivirusAge DistributionPredictive Value of TestsRisk FactorsVirologyPrevalenceHumansChildSicilyAgedAged 80 and overHepaciviruRisk FactorGeneral populationAlanine TransaminaseHepatitis B viruHepatitis C AntibodiesMiddle AgedHepatitis BHepatitis CPopulation SurveillanceFemaleHepatitis C viruHepatitis C AntibodieHuman
researchProduct

Rickettsia typhi and Haemophagocytic Syndrome

2017

Appropriate therapy (dexamethasone, cyclosporin, and etoposide) could save the patient in those cases in which the pathogen-direct therapy has not been sufficient by itself to control the disease.

AdultMaleFeverVomiting030231 tropical medicineTime-to-Treatment03 medical and health sciences0302 clinical medicineFatal OutcomeVirologyRickettsia typhiMedicineAnimalsHumansTreatment FailureRickettsia prowazekiiRickettsia typhileishmaniasisLetter to the EditorTransaminasesAgedAged 80 and overbiologybusiness.industryNauseaTyphus Endemic Flea-BorneExanthemaMiddle Agedbiology.organism_classificationVirologyTexasThrombocytopeniaAnti-Bacterial AgentsInfectious Diseases030211 gastroenterology & hepatologyParasitologyFemalebusinessTyphus Epidemic Louse-BorneThe American Journal of Tropical Medicine and Hygiene
researchProduct

Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B

2013

Treatment with peginterferon α-2a (PegIFN) for 48 weeks is the standard of care for selected HBeAg-negative patients chronically infected with hepatitis B virus (HBV), but with limited treatment efficacy. A study was undertaken to investigate whether treatment extension to 96 weeks improves the outcome in this patient population.128 HBeAg-negative patients (120 genotype D) were randomised to weekly 180 μg PegIFN for 48 weeks (group A, n=51), 180 μg PegIFN for 48 weeks followed by 135 μg weekly for an additional 48 weeks (group B, n=52) or 180 μg PegIFN plus lamivudine (100 mg/day) for 48 weeks then 135 μg PegIFN for 48 weeks (group C, n=25). Endpoints were alanine aminotransferase normalisa…

AdultMaleHBsAgmedicine.medical_specialtyHepatitis B virusTime FactorsAnti-HIV Agentsmedicine.disease_causeGastroenterologyAntiviral AgentsGroup Blaw.inventionPolyethylene GlycolsPharmacotherapyHepatitis B ChronicRandomized controlled triallawPegylated interferonInternal medicinemedicineHumansHepatitis B e AntigensHepatitis B virusbusiness.industryGastroenterologyLamivudineInterferon-alphaAlanine TransaminaseHepatitis BMiddle Agedmedicine.diseaseHepatitis BRecombinant ProteinsTreatment OutcomeLamivudineImmunologyDNA ViralInterferonDrug Therapy CombinationFemaleHepatitis B; Interferonbusinessmedicine.drug
researchProduct